The pharmaceutical supply chain is facing a rapidly changing environment shaped by global disruptions, evolving regulatory requirements, increasing product complexity, cybersecurity risks, and growing demands for speed and resilience. As companies look to strengthen their operations, building supply chains that are agile, responsive, streamlined, and secure has become a strategic priority.
Against this backdrop, Pharma…
The pharmaceutical and healthcare industries are entering a new era of technology-led transformation, with artificial intelligence, machine learning, data science, informatics, and advanced data management reshaping how medicines are discovered, developed, and delivered.
Against this backdrop, Digi-Tech Pharma & AI 2027 will bring together senior professionals, technology leaders, decision-makers, and innovators from the pharmaceutical, biotechnology,…
Shots
Pelareorep is gaining regulatory momentum through multiple FDA interactions and Fast Track designations, providing greater clarity around potential registration pathways and shaping Oncolytics’ clinical development and partnership strategy.
REO-033 could mark a pivotal step toward registration as the randomized study in RAS-mutant MSS metastatic colorectal cancer builds on encouraging clinical data and has the potential to become…
As clinical trials become increasingly complex and technology-driven, the need for smarter strategies, stronger collaborations, and patient-centric innovation has never been greater. From decentralized clinical trials and artificial intelligence to advanced data management and evolving regulatory frameworks, the clinical research landscape is undergoing a significant transformation.
Global Clinical Trials Connect 2027 aims to bring together…
BIOPLUS-INTERPHEX KOREA (BIX) 2026 is Korea's premier biopharmaceutical business event, bringing together global leaders across the entire biopharmaceutical value chain. Scheduled to take place from October 28-30, 2026, at COEX, Seoul, South Korea, the event serves as a platform for innovation, knowledge exchange, technology showcase, and strategic business partnerships.
From drug discovery and clinical development…
An Interview with Priyanka Joshi, Associate Scientist in Analytical Development
Introduction
Cancer remains one of the world's greatest healthcare challenges, driving scientists to develop more effective and precise treatment approaches. Among the most promising innovations are cell therapies, which harness the body's own immune system to fight cancer. Behind these advances are scientists working to…
The pharmaceutical industry is entering a new era where innovation is no longer driven by individual organisations alone. From drug discovery and clinical research to manufacturing, regulatory compliance, digital transformation, and global commercialisation, success increasingly depends on strategic partnerships that combine expertise, technology, and shared ambition.
The Global Pharma Partnering Summit 2026 serves as a…
Advance forecasting, AI and analytics to drive strategic commercial decision-making across functions in Pharma
The Marcus Evans AI, Forecasting, Insights and Analytics for Smarter Decisions in Pharma conference will explore how pharma leaders are embedding Gen AI for long-term forecasting, Agentic AI for Real-World-Evidence generation and advanced analytics into cross-functional workflows to improve forecasting confidence, commercial responsiveness and long-term strategic planning…
Shots
United Imaging is advancing the future of radiology through the convergence of ultra-high-field imaging and AI, with the uMR Jupiter 5T enabling unprecedented anatomical and functional visualization while next-generation AI transforms imaging data into actionable clinical insights that support earlier diagnosis, precision medicine, and personalized patient care.
At HLTH Europe 2026, the company highlighted how 5T whole-body MRI expands clinical…
Shots:
Blue Earth Diagnostics is advancing precision molecular imaging in prostate cancer through its F-18 PET imaging portfolio, with POSLUMA and Axumin designed to improve disease localization, support earlier clinical decision-making, and enhance physician confidence, particularly in patients experiencing biochemical recurrence.
At SNMMI 2026, the company presented new evidence highlighting POSLUMA's strong detection performance at low PSA levels, reduced urinary…

